<DOC>
	<DOCNO>NCT02611544</DOCNO>
	<brief_summary>Fear cancer recurrence ( FCR ) one prevalent , persistent , disruptive source distress adult cancer survivor . Prevalence rate FCR estimate 89 % , approximately half cancer survivor report clinically significant level FCR . Despite recognize prevalence , persistence , suffer associate FCR , effective accessible treatment FCR lack urgently need . Our long-term goal develop , evaluate , implement effective behavioral intervention cancer survivor suffer FCR .</brief_summary>
	<brief_title>Investigation Three Approaches Address Fear Recurrence Among Breast Cancer Survivors</brief_title>
	<detailed_description>The propose randomized pilot study assess effect novel therapeutic intervention—Acceptance Commitment Therapy ( ACT ) —for breast cancer survivor ( BCS ) clinically-significant FCR . ACT spiritually-sensitive behavioral therapy show efficacy treatment anxiety non-cancer population , preliminary efficacy improve variety outcome among adults cancer . ACT use mindfulness acceptance process , along committed behavior change service individual 's deeply hold value enhance psychological flexibility encourage adaptive cop life challenge , cancer . The primary objective propose 3-arm randomize control pilot trial ass feasibility/acceptability determine preliminary effect size estimate ACT preparation fully-powered efficacy trial . A total 78 BCS complete curative treatment report clinically-significant FCR ( define score ≥ 13 Fears Cancer Recurrence Inventory-Short Form ) randomize one three group : ( 1 ) 6-week ACT intervention group ( n=26 ) ; ( 2 ) 6-week survivorship education group ( SE ; n=26 ) ; ( 3 ) usual care ( UC ; n=26 ) . The impact ACT , SE , UC survivor ' FCR associate psychological , spiritual , biological ( telomere length ) outcome examine baseline ( T1 ) , post-intervention ( T2 ) , 1-month ( T3 ) , 6-month follow-up ( T4 ) follow specific aim : Aim 1 : Evaluate feasibility acceptability ACT , SE , UC accord : 1 . Percentage eligible BCS consent participate trial ; 2 . Attendance rate across 6 session ACT SE ; 3 . Retention rate T4 ACT , SE , UC arm ; 4 . Mean rating across group intervention satisfaction helpfulness manage FCR . Aim 2 : Determine pairwise effect size estimate ACT , SE , UC effect time point ( T2 , T3 , T4 ) adjust T1 : 1 . Primary outcome : reducing FCR ; 2 . Secondary psychological outcome : experiential avoidance , cognitive avoidance , anxiety , depression , post-traumatic stress symptom , vitality , breast cancer self-efficacy , quality life ; 3 . Secondary spiritual outcome : spiritual well-being mindfulness ; 4 . Secondary biological outcome : telomere length .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Mammary Neoplasms , Animal</mesh_term>
	<mesh_term>Remission , Spontaneous</mesh_term>
	<mesh_term>Neoplasm Regression , Spontaneous</mesh_term>
	<criteria>Participants study eligible : 1. age ≥18 year , 2. diagnose nonmetastatic breast cancer ( stag 0III ) , 3. complete curative treatment breast cancer , 4. experience cancer recurrence , 5. report clinically significant level FCR ( assess Fear Cancer Recurrence InventoryShort Form ≥ 13 ) 1. severe depression ( PHQ8 ≥ 20 ) , 2. past participation ACT formal mindfulness training , 3. limited English proficiency .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fear Cancer Recurrence</keyword>
	<keyword>Fear Cancer Return</keyword>
	<keyword>Breast Cancer Survivor</keyword>
	<keyword>Breast Cancer Remission</keyword>
</DOC>